Community-acquired pneumonia (CAP), one of the most common serious infections in childhood, is responsible for approximately 1.5 million ambulatory visits in children annually in the US.
1 Professional society guidelines recommend 10 days of antibiotic therapy for outpatient CAP but acknowledge that shorter courses of therapy may be equally effective.
2 Limiting antibiotic use to the shortest possible effective duration is critical to reducing adverse effects of antibiotic treatment and the spread of antimicrobial resistance.
3,4 Several randomized clinical trials have demonstrated noninferiority of shorter treatment durations in children,
5,6 including a recent trial in Canada
7 that found that 5 days of amoxicillin therapy was noninferior to 10 days for treatment of CAP in children younger than 10 years. However, these studies were designed as noninferiority efficacy trials and did not comprehensively consider potential antibiotic-associated adverse effects, an important patient-centered outcome that impacts patient experience, treatment adherence, and efficacy. None of the aforementioned studies examined potential associations between treatment duration and its impact on the reservoir of antibiotic resistance genes in the respiratory tract microbiome (ie, the resistome).
2,8